Epidemiology Director
Medical Evidence, Vaccines & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK, United Kingdom
Wilhelmine Meeraus works as an Epidemiology Director at AstraZeneca. She is the Global Medical Evidence lead for Influenza, and chairs the Evidence Review Team; a governance committee that ensures AstraZeneca observational studies are methodologically robust. She is also involved with multiple cross-pharma initiatives and consortiums for vaccine development. Dr Meeraus has roots in public health and extensive experience in observational studies using real-world data. She has worked across a number of therapy areas, both in the public and private sector, including in public health institutes, academia, the UK medicines regulator, and the pharmaceutical industry. Dr Meeraus’ career began in infectious disease surveillance and control. She has since developed expertise in the fields of medication safety, infections in pregnancy, respiratory epidemiology, and more recently, COVID-19, RSV and influenza vaccines. She has a Masters degree from the London School of Hygiene and Tropical Medicine (UK) and a PhD in Epidemiology from University College London (UK).